Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors

Constantin A. Dasanu, Shounak Majumder, Srila Gopal, Elena Stoica-Mustafa, Guru Trikudanathan

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Introduction: Several chemotherapy agents and combinations have proven effective in the therapy of advanced enteropancreatic neuroendocrine tumors (EP-NETs). However, their toxicity can be significant. Recent understanding of the molecular mechanisms of these tumors, especially the central role of tumor angiogenesis, has led to the identification of new therapeutic targets and agents directed at the molecular level. Areas covered: This paper gives a comprehensive evaluation of the existing therapeutic armamentarium for EP-NETs. Narrated in a historical perspective, this review analyzes the available information on traditional chemotherapy agents, interferon-α and somatostatin analogs, as well as newer therapies and experimental agents. Expert opinion: Despite recent advances, a curative approach for metastatic EP-NETs is yet to be discovered. To date, sunitinib and everolimus have been shown to impact progression-free survival only in pancreatic NETs, and the duration of this benefit has not yet been established. Further research is necessary to determine whether a combination of these drugs, either together or with other therapies, may yield superior outcomes. Moreover, sequential use of these agents should be explored in an attempt to improve survival. Efficacy of a variety of experimental agents is also being tested in clinical trials.

Original languageEnglish (US)
Pages (from-to)461-471
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number4
DOIs
StatePublished - Mar 1 2012

Keywords

  • Chemotherapy
  • Enteropancreatic neuroendocrine tumors (EP-NETs)
  • Everolimus
  • Somatostatin analogs
  • Sunitinib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors'. Together they form a unique fingerprint.

  • Cite this